Navigation Links
Cardiome To Release Third Quarter Results
Date:11/12/2007

NASDAQ: CRME TSX: COM

VANCOUVER, Nov. 12 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it will report 2007 third quarter financial results on the afternoon of Tuesday, November 13, 2007. Cardiome will hold a teleconference call and webcast at 4:30pm Eastern Time (1:30pm Pacific Time) on that day to discuss the results.

To access the conference call, please dial 416-340-8010 or 866-540-8136. There will be a separate dial-in line for analysts on which we will respond to questions at the end of the call. The webcast can be accessed through Cardiome's website at http://www.cardiome.com.

Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through December 10, 2007. Please dial 416-695-5800 or 800-408-3053 and enter code 3242180 followed by the number sign to access the replay.

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at http://www.sec.gov and the Canadian securities regulatory authorities at http://www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

CONTACT: Peter K. Hofman, Senior Director, Investor Relations, (604) 676-6993, or Toll Free: 1-800-330-9928, Email: phofman@cardiome.com


'/>"/>
SOURCE Cardiome Pharma Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiome to Present at Bear Stearns Conference
2. Cardiome to Present at ThinkEquity Conference
3. Cardiome to Present at CIBC Conference
4. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
5. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
6. First New York/New Jersey Health Care Report Card Released
7. Cleveland Clinic Press Releases Journal-Writing Book Write for Life: Healing Body, Mind, and Spirit Through Journal Writing by Sheppard B. Kominars, Ph.D.
8. Robbins & Myers to Release Fourth Quarter and 2007 Fiscal Year Results on Monday, October 15, 2007
9. Leading Child Abuse Center Releases Back to School Tips to Protect Children From Internet Predators
10. Kensey Nash Corporation Announces its First Quarter 2008 Earnings Release Date and Teleconference
11. JHA Releases 2007 U.S. Group Disability Mid-Year Market Survey Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... Washington, DC (PRWEB) , ... May 24, 2017 ... ... The Center for Global Policy Solutions is vehemently opposed to Donald Trump’s budget, ... old formula for despair that inspires fear, demonizes the poor, marginalizes underserved populations, ...
(Date:5/24/2017)... ... 24, 2017 , ... Accordant Technology, a trusted IT solutions ... an analytics-first approach, layered with machine learning, that provides real-time visibility into the ... cloud to the edge. Through the new partnership, customers get the real-time situational ...
(Date:5/24/2017)... River Falls, Wisconsin (PRWEB) , ... May 24, ... ... market leader in clean label food ingredient solutions for the food and beverage ... consumers factor in food ingredient statements during the purchasing decision process. As a ...
(Date:5/23/2017)... ... May 23, 2017 , ... Allegheny Health Network and ... Joy D’Achille Center for Women’s Behavioral Health at West Penn Hospital , a ... for women suffering from pregnancy-related depression. Construction of the Center is underway with ...
(Date:5/23/2017)... ... May 23, 2017 , ... The ... professionals, is pleased to announce the organization’s Certified Strength Coach credential has earned ... Strength Coach (CSC) program validates the competency of qualified candidates for jobs in ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... , May 4, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... and big data solutions, today announced that it is ... and STI Technologies Limited to lower diabetes healthcare costs ... STI,s innoviCares card, which is available throughout all provinces ... customers will be eligible for additional savings when shopping ...
(Date:5/4/2017)... BOTHELL, Wash. , May 4, 2017   ... a leading developer, manufacturer and marketer of proprietary clinical ... media ("BioLife" or the "Company"), today announced that ... released after market close on Thursday, May 11, 2017, ... and live webcast at 1:30 p.m. PT that afternoon. ...
(Date:5/3/2017)... , May 3, 2017  Kalorama Information ... of nine percent next year and this is ... and hematopoietic stem cell (HSCT) or bone marrow ... testing technologies are well-suited for this task. This ... research publisher Kalorama Information. The various PCR-based methodologies, ...
Breaking Medicine Technology: